Background: As the cost of cancer care continues to rise, biosimilars provide an important
cost-saving treatment option. Thus, understanding barriers to biosimilar uptake, including …

PURPOSE: Despite increasing availability of biosimilar cancer treatments, little is known
about oncologists' knowledge and concerns regarding biosimilar use in the United States …

35 Background: Despite the increasing availability of biosimilar cancer treatments, little is
known about oncologists' knowledge and concerns about biosimilar use in the United …

Aim: We aimed to improve oncology patients' knowledge and awareness of biosimilars.
Subsequently, we conducted an assessment of this knowledge by use of an anonymous …

Background: With increasing numbers of oncology biosimilars in the approval pipeline, it is
important to investigate oncology clinicians' understanding of biosimilars and what …

Biosimilar agents are biologic products that have been shown to be" highly similar" to an
already approved reference biologic product. Their integration into clinical practice has the …

e18813 Background: Use of biosimilars is an effective strategy in expanding access to care
and lowering healthcare costs. Literature about the successes, challenges, and best …

Biosimilars will enter the US market soon, potentially lowering costs and increasing patient
access to important oncology biologics. Biosimilars are highly similar, but not identical, to …

In the article accompanying this editorial, Bloomfield and colleagues report a meta-analysis
of published clinical trials evaluating 3 disease-modifying biosimilar oncology drugs. 1 …

Biosimilarsare nonpatented biologic products that are similar to reference biologic agents in
structure, function, activity, safety, and efficacy. In 2014, investigators from the RAND …